PT  - JOURNAL ARTICLE
AU  - Hwalin, Yi
AU  - Yun, Yejin
AU  - Choi, Won Hoon
AU  - Hwang, Hye-Yeon
AU  - Cha, Ju Hyuen
AU  - Seok, Heeyoung
AU  - Song, Jae-Jin
AU  - Lee, Jun Ho
AU  - Oh, Seung Ha
AU  - Lee, Sang-Yeon
AU  - Kim, Daesik
TI  - CRISPR-based editing strategies to rectify <em>EYA1</em> complex genomic rearrangement linked to haploinsufficiency
AID  - 10.1101/2023.11.14.23298277
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.14.23298277
4099  - http://medrxiv.org/content/early/2023/11/15/2023.11.14.23298277.short
4100  - http://medrxiv.org/content/early/2023/11/15/2023.11.14.23298277.full
AB  - Pathogenic structure variations (SVs) and genomic rearrangements are associated with various types of cancer and rare genetic diseases. Recent studies have used Cas9 nuclease with paired guide RNAs (gRNAs) to generate targeted chromosomal rearrangements. Studies on Cas9-mediated translocations and inversions have mainly focused on producing fusion proteins that cause cancer, whereas research on precision genome editing for rectifying SVs is limited. In this study, through whole- genome sequencing, we identified a novel complex genomic rearrangement (CGR), specifically an EYA1 inversion with a deletion, implicated in branchio-oto- renal/branchio-oto (BOR/BO) syndrome. The CGR results in a loss-of-function allele, leading to haploinsufficiency. To address this, two CRISPR-based editing approaches were tested. First, we engineered Cas9 nuclease and paired gRNAs tailored to the patient’s genome. The dual CRISPR/Cas9 system induced efficient editing at sites with paracentric inversion in patient-derived fibroblasts (up to 1.6%), and effectively restored the expression levels of the EYA1 gene and its downstream targets, restoring overall transcriptional functionality. Additionally, we engineered gene-activating CRISPR-Cas modules (CRISPRa), which increased EYA1 mRNA and protein expression to wild-type levels in human EYA1 monoallelic knockout cells that mimic the haploinsufficiency. Moreover, CRISPRa significantly improved transcriptional activity essential for target gene expression. This suggests that CRISPRa-based gene therapies may offer substantial translational potential for approximately 70% of disease-causing EYA1 variants responsible for haploinsufficiency. In parallel to deciphering the complexities of the genomic landscape related to human genetic disorders, our findings demonstrate the potential of CIRSPR-guided genome editing for correcting SVs, including those with EYA1 CGR linked to haploinsufficiency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported and funded by SNUH Kun-hee Lee Child Cancer & Rare Disease Project, Republic of Korea (FP-2022-00001-004 to S-Y. Lee), National Research Foundation of Korea (NRF) and funded by the Ministry of Education (grant number: 2022R1C1C1003147 to Sang-Yeon Lee), SNUH Research Fund (04-2022-4010 to S-Y. Lee and 04-2022-3070 to S-Y. Lee), National Research Foundation of Korea (2020R1A2C2101714 to D.K), Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korean government (Ministry of Science and ICT, Ministry of Health & Welfare [21A0202L1-12 to D.K.]), and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI21C1314 and HR22C1363 to D.K.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Seoul National University Hospital gaved ethical approval for this work (IRB-H-0905-041-281 and IRB-H-2202-045-1298).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors